Results 181 to 188 of about 13,526 (188)

A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors

Annals of Oncology, 2015
Filippo de Braud, Stefano Cascinu, T de Pas   +2 more
exaly  

Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON

Respirology, 2020
Jin Woo Song, Bruno Crestani, Takashi Ogura   +2 more
exaly  

A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.

American Journal of Respiratory Cell and Molecular Biology, 2017
Oliver Eickelberg, PD Dr. Claudia Staab-Weijnitz, Juergen Behr   +2 more
exaly  

Nintedanib Reduces Neutrophil Chemotaxis via Activating GRK2 in Bleomycin-Induced Pulmonary Fibrosis

International Journal of Molecular Sciences, 2020
Vincent Yi-Fong Su, Kuang-Yao Yang, Hsin-Pai Chen   +2 more
exaly  

Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer

Journal of Clinical Pharmacology, 2016
Rolf Kaiser, Peter Stopfer, Claudia Dallinger   +2 more
exaly  

A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results

British Journal of Cancer, 2015
Igor N. Bondarenko, Timothy Eisen, N Macleod   +2 more
exaly  

A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients

Annals of Oncology, 2015
Alfredo Carrato, Jaume Capdevila, Eric Van Cutsem   +2 more
exaly  

Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis

European Journal of Clinical Pharmacology
Wei Wan
exaly